期刊
CHEMICAL RESEARCH IN TOXICOLOGY
卷 28, 期 7, 页码 1391-1397出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.chemrestox.5b00208
关键词
-
资金
- European Research Council (CONNECT)
- European Union (FP7)
- Cosmetics Europe (DETECTIVE)
- Fund for Scientific Research, Flanders (FWO-Vlaanderen)
- Sao, Paulo Research Foundation, Brazil (FAPESP)
- University of sao Paulo, Brazil (USP)
- University Hospital of the Vrije Universiteit Brussel, Belgium (Willy Gepts Fonds UZ - VUB)
- Cosmetics Europe (HeMiBio)
Drug-induced liver injury is a prominent reason for premarketing and postmarketing drug withdrawal and can be manifested in a number of ways, such as cholestasis, steatosis, and fibrosis. The mechanisms driving these toxicological processes have been well characterized and have been emdedded in adverse outcome pathway frameworks in recent years. This review evaluates these constructs and simultaneously illustrates their use in the preclinical testing of drug-induced liver injury.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据